274 related articles for article (PubMed ID: 28351793)
1. Nivolumab-Associated Colitis Mimicking Ulcerative Colitis.
Kubo K; Kato M; Mabe K
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):A35-A36. PubMed ID: 28351793
[No Abstract] [Full Text] [Related]
2. Nivolumab-Induced Colitis Treated by Infliximab.
Yanai S; Nakamura S; Matsumoto T
Clin Gastroenterol Hepatol; 2017 Apr; 15(4):e80-e81. PubMed ID: 27664866
[No Abstract] [Full Text] [Related]
3. A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine.
Kikuchi H; Sakuraba H; Akemoto Y; Murai Y; Fukutoku Y; Asari T; Tatsuta T; Hasui K; Hiraga H; Sawaya M; Chinda D; Mikami T; Tanaka M; Fukuda S
Immunol Med; 2019 Mar; 42(1):39-44. PubMed ID: 30917094
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint Inhibitors May Cause Pseudoprogression and Dose-Limiting Side Effects.
Wiley K
ONS Connect; 2016 Jul; 31(7):24. PubMed ID: 30549937
[No Abstract] [Full Text] [Related]
5. Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike-report of new cases and review of the literature.
Cañete F; Mañosa M; Lobatón T; Mesonero F; Rodríguez-Lago I; Cabré E; Cabriada JL; López-Sanromán A; Domènech E
Int J Colorectal Dis; 2019 May; 34(5):861-865. PubMed ID: 30826963
[TBL] [Abstract][Full Text] [Related]
6. Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient.
Teramoto Y; Nakamura Y; Asami Y; Imamura T; Takahira S; Nemoto M; Sakai G; Shimada A; Noda M; Yamamoto A
J Dermatol; 2017 May; 44(5):605-606. PubMed ID: 27334247
[No Abstract] [Full Text] [Related]
7. Multiple Cranial Neuropathies From Nivolumab in a Patient With Metastatic Hepatocellular Carcinoma.
Siegel CH; Finn RS; Ho MG
Mayo Clin Proc; 2018 Apr; 93(4):540-541. PubMed ID: 29622100
[No Abstract] [Full Text] [Related]
8. [Histoseminar on inflammatory bowel diseases (IBD): Case n
Fléjou JF
Ann Pathol; 2017 Aug; 37(4):298-301. PubMed ID: 28734677
[No Abstract] [Full Text] [Related]
9. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.
Sato M; Uhara H; Koga H; Okuyama R
J Dermatol; 2018 Oct; 45(10):e287-e289. PubMed ID: 29655228
[No Abstract] [Full Text] [Related]
10. Nivolumab plus ipilimumab in metastatic colorectal cancer.
Gourd E
Lancet Oncol; 2018 Mar; 19(3):e139. PubMed ID: 29395861
[No Abstract] [Full Text] [Related]
11. Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinoma of the prostate.
Eze C; Manapov F; Gratzke C; Schmidt-Hegemann NS; Jung A; Kirchner T; Heinemann V; Stief CG; Belka C; Boeck S
Eur J Cancer; 2018 May; 95():109-111. PubMed ID: 29477368
[No Abstract] [Full Text] [Related]
12. Mucosal Lichen Planus Mimicking Mucosal Lesions in Stevens-Johnson Syndrome after Nivolumab Therapy.
Miyagawa F; Nakajima A; Ohyama SI; Aoki Y; Nishikawa M; Nakamura Y; Hashimoto T; Asada H
Acta Derm Venereol; 2019 Jun; 99(7):687-688. PubMed ID: 30938822
[No Abstract] [Full Text] [Related]
13. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
[No Abstract] [Full Text] [Related]
14. Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer.
Kuraoka N; Hara K; Terai S; Yatabe Y; Horio Y
Endoscopy; 2018 Sep; 50(9):E259-E261. PubMed ID: 29969801
[No Abstract] [Full Text] [Related]
15. Case of acute-onset type 1 diabetes induced by long-term immunotherapy with nivolumab in a patient with mucosal melanoma.
Maekawa T; Okada K; Okada H; Kado S; Kamiya K; Komine M; Murata S; Oka K; Ishibashi S; Ohtsuki M
J Dermatol; 2019 Dec; 46(12):e463-e464. PubMed ID: 31436330
[No Abstract] [Full Text] [Related]
16. Dramatic effect of nivolumab against melanoma and immune-related liver toxicity: A detailed histopathological and immunohistochemical analysis of nivolumab-induced liver toxicity.
Namiki T; Nojima K; Chikazawa S; Iwamoto Y; Otsuki Y; Albusani H; Miura K; Kiyokawa Y; Asakage T; Yokozeki H
J Dermatol; 2019 May; 46(5):e182-e183. PubMed ID: 30474878
[No Abstract] [Full Text] [Related]
17. Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab.
Fujimura T; Lyu C; Tsukada A; Sato Y; Kambayashi Y; Aiba S
J Dermatol; 2019 May; 46(5):e177-e178. PubMed ID: 30353913
[No Abstract] [Full Text] [Related]
18. Nivolumab-induced colitis in a patient with malignant melanoma: A case report and immunological analysis.
Miyashita A; Fukushima S; Tsukamoto H; Itai H; Miyamoto H; Nakahara S; Kubo Y; Kimura T; Kuriyama H; Ihn H
J Dermatol; 2019 Sep; 46(9):e339-e341. PubMed ID: 30908699
[No Abstract] [Full Text] [Related]
19. Infliximab for severe colitis associated with nivolumab followed by ipilimumab.
Fukumoto T; Fujiwara S; Tajima S; Tamesada Y; Sakaguchi M; Oka M; Nishigori C
J Dermatol; 2018 Jan; 45(1):e1-e2. PubMed ID: 28891241
[No Abstract] [Full Text] [Related]
20. Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma.
Dasanu CA
J Oncol Pharm Pract; 2019 Dec; 25(8):2052-2055. PubMed ID: 30782092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
